William J. Hogan

15.6k total citations · 1 hit paper
413 papers, 7.1k citations indexed

About

William J. Hogan is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, William J. Hogan has authored 413 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 268 papers in Hematology, 129 papers in Genetics and 86 papers in Molecular Biology. Recurrent topics in William J. Hogan's work include Acute Myeloid Leukemia Research (112 papers), Hematopoietic Stem Cell Transplantation (93 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (80 papers). William J. Hogan is often cited by papers focused on Acute Myeloid Leukemia Research (112 papers), Hematopoietic Stem Cell Transplantation (93 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (80 papers). William J. Hogan collaborates with scholars based in United States, Saudi Arabia and Australia. William J. Hogan's co-authors include Mark R. Litzow, Ayalew Tefferi, Angela Dispenzieri, Martha Q. Lacy, Morie A. Gertz, Animesh Pardanani, Shaji Kumar, Francis K. Buadi, David Dingli and Suzanne R. Hayman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

William J. Hogan

384 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

2006 758 citations Animesh Pardanani, Michelle A. Elliott et al. Blood profile →

Peers

Countries citing papers authored by William J. Hogan

Since Specialization

Citations

This map shows the geographic impact of William J. Hogan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William J. Hogan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William J. Hogan more than expected).

Fields of papers citing papers by William J. Hogan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William J. Hogan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William J. Hogan. The network helps show where William J. Hogan may publish in the future.

Co-authorship network of co-authors of William J. Hogan

This figure shows the co-authorship network connecting the top 25 collaborators of William J. Hogan. A scholar is included among the top collaborators of William J. Hogan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William J. Hogan. William J. Hogan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes of HLA-DPB1 Mismatch in Patients Receiving Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prophylaxis 2024 ·Transplantation and Cellular Therapy ·(unknown), Anmol Baranwal, (unknown), Mehrdad Hefazi, Abhishek A. Mangaonkar, Mithun Vinod Shah, Mark R. Litzow, William J. Hogan, Manish J. Gandhi, Hassan B. Alkhateeb	0
2	Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series 2024 ·Blood ·Talha Badar, (unknown), (unknown), James M. Foran, Mohamed A. Kharfan‐Dabaja, Hemant S. Murthy, Naseema Gangat, Aref Al‐Kali, Mithun Vinod Shah, Hassan B. Alkhateeb, Antoine N. Saliba, William J. Hogan, (unknown), Lisa Sproat, Jeanne Palmer, Mark R. Litzow, Mrinal M. Patnaik	1
3	Open-world Semi-supervised Generalized Relation Discovery Aligned in a Real-world Setting 2023 ·William J. Hogan, Jiacheng Li, Jingbo Shang	3
4	Venetoclax + Cladribine + Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax + Hypomethylating Agent 2023 ·Blood ·(unknown), Kristen McCullough, Aref Al‐Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek A. Mangaonkar, Antoine N. Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun Vinod Shah, Animesh Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, (unknown), Ayalew Tefferi, Naseema Gangat	1
5	Factors Predicting Survival Following Allogeneic Stem Cell Transplant in Patients with Therapy-Related Myeloid Neoplasms 2022 ·Transplantation and Cellular Therapy ·Anmol Baranwal, Rakchha Chhetri, Chung Hoow Kok, Hassan B. Alkhateeb, Abhishek A. Mangaonkar, (unknown), (unknown), (unknown), Peter Bardy, William J. Hogan, Mark R. Litzow, Devendra Hiwase, Mithun Vinod Shah	2
6	Allogeneic Stem Cell Transplant Outcomes in Patients with DDX41 Mutated Myeloid Malignancies 2022 ·Transplantation and Cellular Therapy ·Anmol Baranwal, Aref Al‐Kali, James M. Foran, David S. Viswanatha, Rong He, Mrinal M. Patnaik, Abhishek A. Mangaonkar, Mithun Vinod Shah, Mark R. Litzow, William J. Hogan, Hassan B. Alkhateeb	1
7	European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response 2022 ·Blood Cancer Journal ·Kebede H. Begna, (unknown), Naseema Gangat, Hassan B. Alkhateeb, Mrinal M. Patnaik, Aref Al‐Kali, M. A. Elliott, William J. Hogan, Mark R. Litzow, Animesh Pardanani, Curtis A. Hanson, Rhett P. Ketterling, Ayalew Tefferi	4
8	Clinical Outcomes of Post Allogeneic Stem Cell Transplant Splenectomy in Primary Myelofibrosis for Delayed Engraftment 2021 ·Transplantation and Cellular Therapy ·(unknown), Mark R. Litzow, Mithun Vinod Shah, William J. Hogan, Hassan B. Alkhateeb	0
9	Comparative study of therapy‐related and de novo adult b‐cell acute lymphoblastic leukaemia 2021 ·British Journal of Haematology ·Zaid Abdel Rahman, Ricardo Parrondo, Michael G. Heckman, (unknown), Kevin C. Miller, Hassan B. Alkhateeb, (unknown), Hemant S. Murthy, William J. Hogan, Mohamed A. Kharfan‐Dabaja, Jess F. Peterson, Linda B. Baughn, Nicole L. Hoppman, Mark R. Litzow, Rhett P. Ketterling, Patricia T. Greipp, James M. Foran	7
10	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy 2021 ·American Journal of Hematology ·Kebede H. Begna, Naseema Gangat, Aref Al‐Kali, Mark R. Litzow, William J. Hogan, Mrinal M. Patnaik, Animesh Pardanani, C. Christopher Hook, Alexandra P. Wolanskyj, Michelle A. Elliott, Curtis A. Hanson, Rhett P. Ketterling, Ayalew Tefferi	4
11	A novel Iowa–Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction 2021 ·Blood Cancer Journal ·Kalyan Nadiminti, (unknown), (unknown), Mehrdad Hefazi, (unknown), Yogesh Jethava, (unknown), Hassan B. Alkhateeb, Mark R. Litzow, Mrinal M. Patnaik, Mithun Vinod Shah, William J. Hogan, Umar Farooq, Margarida Silverman, Sarah L. Mott	2
12	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients 2020 ·American Journal of Hematology ·Erika Morsia, Kristen McCullough, (unknown), Joselle Cook, Hassan B. Alkhateeb, Aref Al‐Kali, Kebede H. Begna, Michelle A. Elliott, William J. Hogan, Mark R. Litzow, Mithun Vinod Shah, Animesh Pardanani, Mrinal M. Patnaik, Ayalew Tefferi, Naseema Gangat	89
13	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma 2019 ·American Journal of Hematology ·Abdullah S. Al Saleh, M Hasib Sidiqi, Morie A. Gertz, Eli Muchtar, Martha Q. Lacy, Rahma Warsame, Wilson I. Gonsalves, Taxiarchis Kourelis, William J. Hogan, Suzanne R. Hayman, Prashant Kapoor, Francis K. Buadi, Angela Dispenzieri, David Dingli, Shaji Kumar	12
14	Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience 2019 ·Leukemia & lymphoma ·Firas Baidoun, Dong Chen, Mrinal M. Patnaik, Naseema Gangat, Kebede H. Begna, Michelle A. Elliott, William J. Hogan, Mark R. Litzow, Aref Al‐Kali	2
15	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis 2019 ·American Journal of Hematology ·Abdullah S. Al Saleh, M Hasib Sidiqi, Surbhi Sidana, Eli Muchtar, Angela Dispenzieri, David Dingli, Martha Q. Lacy, Rahma Warsame, Wilson I. Gonsalves, Taxiarchis Kourelis, William J. Hogan, Suzanne R. Hayman, Robert Christian Wolf, Prashant Kapoor, Francis K. Buadi, Shaji Kumar, Morie A. Gertz	13
16	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis 2019 ·American Journal of Hematology ·Surbhi Sidana, M Hasib Sidiqi, Angela Dispenzieri, Francis K. Buadi, Martha Q. Lacy, Eli Muchtar, David Dingli, Suzanne R. Hayman, Wilson I. Gonsalves, Prashant Kapoor, Nelson Leung, Rahma Warsame, Taxiarchis Kourelis, Robert Christian Wolf, William J. Hogan, Shaji Kumar, Morie A. Gertz	31
17	Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias 2019 ·Mayo Clinic Proceedings ·Abhishek A. Mangaonkar, Alejandro Ferrer, Filippo Pinto e Vairo, Margot A. Cousin, (unknown), Naseema Gangat, William J. Hogan, Mark R. Litzow, Tammy M. McAllister, Eric W. Klee, Konstantinos N. Lazaridis, A. Keith Stewart, Mrinal M. Patnaik	12
18	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation 2018 ·British Journal of Haematology ·Rajshekhar Chakraborty, Eli Muchtar, Shaji Kumar, Francis K. Buadi, David Dingli, Angela Dispenzieri, Suzanne R. Hayman, William J. Hogan, Prashant Kapoor, Martha Q. Lacy, Nelson Leung, Rahma Warsame, Taxiarchis Kourelis, Wilson I. Gonsalves, Morie A. Gertz	12
19	Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy 2017 ·Leukemia & lymphoma ·Jason N. Barreto, Kristen McCullough, (unknown), Ross Dierkhising, Kristin C. Mara, Michelle A. Elliott, Dennis A. Gastineau, Aref Al‐Kali, Naseema Gangat, Louis Letendre, William J. Hogan, Mark R. Litzow, Mrinal M. Patnaik	11
20	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation 2015 ·Nephrology Dialysis Transplantation ·Nelson Leung, Shaji Kumar, Siobhán Glavey, Angela Dispenzieri, Martha Q. Lacy, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Prashant Kapoor, Steven R. Zeldenrust, Stephen J. Russell, John A. Lust, William J. Hogan, S. Vincent Rajkumar, Dennis A. Gastineau, Taxiarchis Kourelis, Yi Lin, Wilson I. Gonsalves, Ronald S. Go, Morie A. Gertz	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact